Clin2
NCT07213791Possibly a fitRecruiting

Study of a new drug for FAP-positive cancers

Ovarian NeoplasmsBreast NeoplasmsPancreatic Intraductal NeoplasmsColorectal NeoplasmsEsophageal NeoplasmsStomach NeoplasmsCholangiocarcinoma

Part of Cancer, Digestive system, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.

This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
241 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Your tumor must test positive for a protein called FAP.
  • You must have one of these cancer types: pancreatic, breast (specific types), ovarian, gastric, colorectal, esophageal, or bile duct cancer.
  • You must have already received at least one prior treatment for your cancer (more for some types).
  • Your cancer must have spread or cannot be removed by surgery.
  • You must be in good enough physical condition to be up and around (ECOG score 0 or 1).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06503146Recruiting· Phase 2
New imaging tracer for detecting various cancers

This trial tests a new imaging agent, [18F]FAPI-74, which might help detect certain cancers more clearly. The scan looks for a protein called fibroblast activation protein (FAP) that is often found in tumors. If you have one of the listed cancers and are about to start treatment, this study could help doctors see where the cancer is and how it responds to therapy.

Bethesda, Maryland
NCT07318805Recruiting· Phase 1
A study of PF-08032562 for advanced solid tumors

This study tests a new medicine, PF-08032562, for people with advanced breast or colorectal cancer that has not responded to prior treatments. It aims to see if the drug is safe and can help shrink or slow the cancer.

Duarte, California
NCT06640413Recruiting· Phase 1
Study of radioactive treatment for FAP-positive advanced tumors

This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.

Bergamo, Bergamo
NCT07014254Not yet recruiting
Lu-177 CTR-FAPI for advanced digestive cancers

This trial tests a new radioactive drug that targets a protein called FAP on cancer cells. It is for people with advanced stomach, pancreas, colon, bile duct, or esophageal cancers that have spread and show high FAP levels on a special scan.

Xi'an, Shaanxi
NCT07454642Recruiting· Phase 1
AVA6103 for advanced FAP-positive solid tumors

This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.

Grand Rapids, Michigan
NCT07363369Not yet recruiting· Phase 1
FAP mRNA vaccine study for advanced solid tumors

This study tests a new mRNA vaccine that targets a protein called FAP, which is found in many solid tumors. It is for people whose cancer has not responded to or cannot tolerate standard treatments.

Hear when a new Ovarian Neoplasms trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.